The ICD-10 code for chronic myelocytic leukemia is C92.1, “chronic myeloid leukemia, BCR/ABL-positive.” In the US version, ICD-10-CM, it must be extended to a billable fifth character that records remission status: C92.10 (not having achieved remission), C92.11 (in remission), or C92.12 (in relapse). Getting the code right matters because it follows the patient through billing, drug approvals, cancer registries, and every future clinical record.
As a clinician working with blood disorders, I find that coding questions about CML often reveal deeper questions about the disease itself. This guide covers both: the codes, and the clinical picture behind them.
What Is Chronic Myelocytic Leukemia?
Chronic myelocytic leukemia, more often called chronic myeloid leukemia (CML), is a cancer of the blood-forming stem cells in the bone marrow. It is one of several hematologic cancers classed as myeloproliferative neoplasms, meaning the marrow overproduces myeloid cells.
Its hallmark is the Philadelphia chromosome, formed when pieces of chromosomes 9 and 22 swap places. This creates the BCR-ABL1 fusion gene, which makes a permanently active tyrosine kinase enzyme. The result is uncontrolled production of granulocytes, a type of white blood cell, at every stage of maturity.
ICD-10 Codes for CML and Related Conditions
The C92 category covers myeloid leukemias. Because the name “chronic myelocytic leukemia” is older terminology, it maps to the same code as chronic myeloid leukemia.
| Code (ICD-10-CM) | Description | When it applies |
|---|---|---|
| C92.10 | Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission | New diagnosis, or disease not yet in remission |
| C92.11 | Chronic myeloid leukemia, BCR/ABL-positive, in remission | Documented remission on treatment |
| C92.12 | Chronic myeloid leukemia, BCR/ABL-positive, in relapse | Disease returning after remission |
| C92.2x | Atypical chronic myeloid leukemia, BCR/ABL-negative | CML-like disease without the fusion gene |
| C93.1x | Chronic myelomonocytic leukemia | A different disorder with raised monocytes |
| C91.1x | Chronic lymphocytic leukemia of B-cell type | A lymphoid, not myeloid, leukemia |
Why the Details Matter
- BCR-ABL1 status separates classic CML (C92.1) from atypical CML (C92.2), and only the former is treated with tyrosine kinase inhibitors as standard.
- Remission status must be documented by the clinician; coders should not infer it from lab results alone.
- Look-alike codes for chronic myelomonocytic and chronic lymphocytic leukemia are frequent sources of error because the names are similar.
- Once treatment is complete and no disease remains, some records use Z85.6, personal history of leukemia, though many CML patients remain on active therapy and keep a C92.1 code.
Causes and Risk Factors
CML is caused by an acquired genetic change, not an inherited one, so it does not run in families. In most patients no trigger is found. High-dose radiation exposure is the best-documented risk factor, and the disease becomes more common with age. Unlike many cancers, lifestyle factors such as smoking and diet are not recognized causes.
Signs, Symptoms, and Phases
Many patients have no symptoms and are diagnosed after a routine blood count. When symptoms occur, they include fatigue, night sweats, weight loss, and fullness or discomfort under the left ribs from an enlarged spleen. Some people notice easy bruising or bleeding, which can reflect abnormal platelet numbers or platelet dysfunction.
| Phase | Features |
|---|---|
| Chronic phase | High white cell count with mostly maturing cells; where most patients are diagnosed |
| Accelerated phase | Rising blast cells, worsening counts, new genetic changes |
| Blast phase | Behaves like acute leukemia, with fever, bone pain, and marrow failure |
How CML Is Diagnosed
A complete blood count typically shows a raised white cell count with a left shift, meaning immature granulocytes appear in the blood, often with raised basophils and platelets. Bone marrow biopsy and aspiration confirm the diagnosis, show a crowded, hypercellular marrow, and establish the phase.
The key test is genetic. Cytogenetics identifies the Philadelphia chromosome, while FISH and PCR detect the BCR-ABL1 gene. Quantitative PCR then becomes the main monitoring tool throughout treatment, and its results inform whether remission can be documented for coding.
Treatment and Its Coding Implications
Tyrosine kinase inhibitors (TKIs) revolutionized CML care. Imatinib was the first, followed by dasatinib, nilotinib, bosutinib, and newer agents for resistant disease. Most patients in chronic phase achieve long-term control with a daily tablet and can expect a near-normal life span if they respond well and take treatment consistently.
Allogeneic stem cell transplantation is reserved for patients whose disease resists several TKIs or presents in advanced phase. Some patients with a deep, sustained molecular response may stop their TKI under close monitoring, a strategy called treatment-free remission. From a records perspective, response and relapse should prompt a review of whether C92.10, C92.11, or C92.12 still fits. For broader background, see our leukemia guide.
Documentation Tips for Accurate Coding
Clear clinical notes make accurate coding straightforward. The most useful details to record at each review are:
- The confirmed diagnosis of CML with BCR-ABL1 positivity, rather than a vague “myeloproliferative disorder”
- The current phase: chronic, accelerated, or blast
- Remission status in plain words, stated by the treating clinician
- The current TKI, any change of drug, and the reason, such as intolerance or resistance
- Complications being managed, such as low blood counts or medication side effects
What the Diagnosis Means for Patients
For patients, the code itself matters mostly behind the scenes, supporting insurance approval for long-term TKI therapy and regular PCR testing. What matters day to day is taking medication consistently, keeping monitoring appointments, and reporting side effects early so that treatment can be adjusted rather than stopped.
Contact your hematology team promptly if you develop fever, drenching sweats, unexplained weight loss, new bone pain, left-sided abdominal fullness, or unusual bruising or bleeding, since these can signal that the disease is changing. Any plan to pause or stop a TKI should always be made with your specialist, never alone.
Frequently Asked Questions
Is chronic myelocytic leukemia the same as chronic myeloid leukemia?
Yes. Chronic myelocytic, chronic myelogenous, and chronic myeloid leukemia are different names for the same disease, and all are coded under C92.1.
Is C92.1 a billable code?
In ICD-10-CM, C92.1 is a category heading and needs a fifth character to be billable: C92.10, C92.11, or C92.12. The WHO version of ICD-10, used in many countries, stops at C92.1.
Which code applies to a patient in deep molecular response?
C92.11, in remission, is appropriate when the treating clinician documents remission. If the record does not state remission, C92.10 is generally used until it does.
Does the code change if CML reaches blast phase?
The disease remains classified under chronic myeloid leukemia, but the phase should be clearly documented in the clinical record because it changes treatment and prognosis. Coders should follow current official guidance and local policy.
Key Takeaways
- The chronic myelocytic leukemia ICD-10 code is C92.1, expanded in ICD-10-CM to C92.10, C92.11, or C92.12 by remission status.
- BCR-ABL1-negative atypical CML, chronic myelomonocytic leukemia, and CLL each have separate codes.
- CML is driven by the Philadelphia chromosome and confirmed by genetic testing.
- TKIs give most chronic-phase patients long-term control, and coding should be updated as remission status changes.
